Bio-Techne Corp (TECH) seems to have had a blend of positive and negative fortunes. Q3 2025 earnings results surpassed expectations but its stock underperformed against competitors on certain days. The firm has continuously emphasized its innovation and expansion plans, from presenting at a BofA Health Care conference to highlighting advancements in biomarker detection via RNAscope technologies. There were concerns about NIH funding which affected the stock's performance. Nonetheless, the company declared dividends, got approval for a share repurchase program, and revealed its plans of presenting next-gen solutions at the 2025 American Society of Gene & Cell Therapy. Partnerships have also been on the rise; Leica Biosystems to enable protease-free workflows, and Kytopen for a cellular engineering workflow meant to expedite cell therapy manufacturing. The company also announced new customer experience centre in Düsseldorf, Germany to expand its European outreach. Amidst the developments, there were reports of a negative funding environment and a drop in the target price. The Q3 financial performance illustrated strong growth and the SETUP of shipping Leo, a next generation High-Throughput Simple Western System has been well received by the market.
Bio-Techne Corp TECH News Analytics from Thu, 22 Jun 2023 07:00:00 GMT to Wed, 21 May 2025 20:30:00 GMT -
Rating 2
- Innovation 6
- Information 7
- Rumor 2
